Navigation Links
Atherotech Announces Addition of ApoAI Heart Disease, Diabetes Risk Marker to VAP(R) Test

ApoAI and apoB/apoAI ratio now available with VAP Cholesterol Test at no additional cost

BIRMINGHAM, Ala., March 10 /PRNewswire/ -- Atherotech, Inc., a cardio-diagnostic company, today announced the addition of apolipoprotein A (apoAI) to its VAP(R) Cholesterol Test. The VAP (Vertical Auto Profile) Test is the only single cholesterol test that routinely reports apoAI, apoB, and the apoB/apoAI ratio.

With the addition of this new marker, the VAP Test now reports apoAI and the apoB/apoAI ratio, increasing its clinical utility in the assessment of risk for heart disease, diabetes and other cardiovascular diseases. The new, clinically validated heart disease risk marker is included with the VAP Cholesterol Test at no added cost.

"The new ratio gives physicians and their patients a single, easy-to-understand number that shows the balance between good and bad cholesterol particles and helps determine whether a person's 'high HDL' is really protective," said Atherotech Chief Medical Officer James Ehrlich, M.D. "Numerous large, prospective studies, including INTERHEART and the AMORIS trials, have clearly shown that the apoB/apoAI ratio is superior to all other cardiovascular disease risk marker ratios."

ApoAI is the main protein component of protective HDL cholesterol while apolipoprotein BI00 (apoB) particles are the main component of atherogenic (bad) LDL cholesterol. In general, the lower the apoB/apoAI value, the lower your risk for heart disease. A ratio of 1 to 2 is considered low risk, while a ratio approaching 1 to 1 would be considered high risk, and anything over that -- where the small LDL particles would dominate -- would be very high risk.

ApoAI and Diabetes

The apoB/apoAI ratio is significantly higher in people with metabolic syndrome, which is present in nearly a quarter of the U.S. population and is a precursor to diabetes. In the Collaborative Atorvastatin Diabetes (CARDS) study of diabetic patients, the apoB/apoAI ratio predicted cardiovascular disease and coronary heart disease events and total mortality better than other lipoprotein variables. The apoB/apoAI ratio is also an independent predictor of insulin resistance in non-diabetic subjects.

People with a family history or an existing condition of diabetes, high blood pressure or heart disease - or who are already taking cholesterol-lowering medication - are candidates for the comprehensive VAP Test. In addition, those who don't score within the desirable ranges of the standard cholesterol test (i.e. those with Triglycerides > 150, HDL < 40, LDL > 130, Total Cholesterol > 200) should also opt for the more detailed VAP Test.

The VAP Test reports 20 separate components of blood cholesterol as opposed to four in a standard cholesterol test. It can identify a far greater number of lipid abnormalities (the #1 risk factor for heart disease) than the standard cholesterol test. The VAP Test also identifies markers for metabolic syndrome, a precursor for diabetes.

The VAP Test is available nationwide and covered by most insurance providers, including Medicare and Medicaid. For more information call 877.901.8510 or visit

About Atherotech, Inc.

Atherotech is a cardio-diagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit

SOURCE Atherotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
2. VAP Cholesterol Test From Atherotech Covers 90 Percent of Arizona Insured
3. Atherotech to Exhibit the VAP Test (R) at ACC 2008 Meeting in Chicago
4. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
5. Atherotech to Exhibit the VAP Test at Internal Medicine 2008
6. VAP(R) Cholesterol Test From Atherotech Covers an Additional 9 Million of Florida Insured
7. Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
(Date:11/24/2015)... ... , ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, ... annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to ... Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the department ...
(Date:11/24/2015)... Tampa, Florida (PRWEB) , ... November 24, 2015 ... ... its biggest event of the year and one of the premier annual events ... USA, and ran from 8–11 November 2015, where ISPE hosted the largest number ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics (AMA), led ... also known as Multirotor Grand Prix, to represent the First–Person View (FPV) racing community. ... members have embraced this type of racing and several new model aviation pilots have ...
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
Breaking Biology Technology:
(Date:11/17/2015)... November 17, 2015 Paris ... --> Paris from 17 th ... the biometrics innovation leader, has invented the first combined scanner ... the same scanning surface. Until now two different scanners were ... scanner can capture both on the same surface. This ...
(Date:11/16/2015)... , Nov 16, 2015  Synaptics Inc. ... human interface solutions, today announced expansion of its ... ™ touch controller and display driver integration ... of smartphones. These new TDDI products add to ... (HD resolution), TD4302 (WQHD resolution), and TD4322 (FHD ...
(Date:11/11/2015)... , Nov. 11, 2015   MedNet Solutions , ... spectrum of clinical research, is pleased to announce that it ... Clinical Trials (PCT) event, to be held November 17-19 ... able to view live demonstrations of iMedNet ... learn how iMedNet has been able to deliver ...
Breaking Biology News(10 mins):